{"id":"isosorbide","rwe":[],"_fda":{"id":"616fb1d3-ab4c-40a1-b11a-7a913f0b617c","set_id":"06839534-85b8-42aa-b0e3-079ed236be44","openfda":{"nui":["N0000175415","M0014874","N0000009909"],"upc":["0362559252010","0362559253017"],"unii":["LX1OH63030"],"route":["ORAL"],"rxcui":["311192","311197"],"spl_id":["616fb1d3-ab4c-40a1-b11a-7a913f0b617c"],"brand_name":["Isosorbide Mononitrate"],"spl_set_id":["06839534-85b8-42aa-b0e3-079ed236be44"],"package_ndc":["62559-252-01","62559-253-01"],"product_ndc":["62559-252","62559-253"],"generic_name":["ISOSORBIDE MONONITRATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Nitrates [CS]"],"pharm_class_pe":["Vasodilation [PE]"],"substance_name":["ISOSORBIDE MONONITRATE"],"pharm_class_epc":["Nitrate Vasodilator [EPC]"],"manufacturer_name":["ANI Pharmaceuticals, Inc."],"application_number":["ANDA075147"],"is_original_packager":[true]},"version":"1","warnings":["WARNINGS Amplification of the vasodilatory effects of isosorbide mononitrate by sildenafil can result in severe hypotension. The time course and dose dependence of this interaction have not been studied. Appropriate supportive care has not been studied, but it seems reasonable to treat this as a nitrate overdose, with elevation of the extremities and with central volume expansion. The benefits of isosorbide mononitrate in patients with acute myocardial infarction or congestive heart failure have not been established. Because the effects of isosorbide mononitrate are difficult to terminate rapidly, this drug is not recommended in these settings. If isosorbide mononitrate is used in these conditions, careful clinical or hemodynamic monitoring must be used to avoid the hazards of hypotension and tachycardia."],"pregnancy":["Pregnancy Teratogenic Effects Reproduction studies performed in rats and rabbits at doses of up to 540 and 810 mg/kg/day, respectively, have revealed no evidence of harm to the fetus due to isosorbide mononitrate. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, isosorbide mononitrate should be used during pregnancy only if clearly needed. Nonteratogenic Effects Birth weights, neonatal survival and development, and incidence of stillbirths were adversely affected when pregnant rats were administered oral doses of 540 (but not 270) mg isosorbide mononitrate/kg/day during late gestation and lactation. This dose was associated with decreased maternal body weight gain and decreased maternal motor activity. Species Daily dose (mg/kg) Multiple of MRHD* Based on: Body Weight Body Surface Rabbit 810 1013 375 Rat 900 540 500 360 270 1125 675 625 450 338 195 117 108 78 59 Calculations assume a human weight of 50 kg and human body surface area of 1.46 m 2 , a rabbit weight of 2 kg and rabbit body surface area of 0.163 m 2 , and a rat weight of 150 g and rat body surface area of 0.025 m 2 . *Maximum recommended human dose (MRHD) is 20 mg bid."],"overdosage":["OVERDOSAGE Hemodynamic Effects The ill effects of isosorbide mononitrate overdose are generally the results of isosorbide mononitrate’s capacity to induce vasodilatation, venous pooling, reduced cardiac output, and hypotension. These hemodynamic changes may have protean manifestations, including increased intracranial pressure, with any or all of persistent throbbing headache, confusion, and moderate fever; vertigo; palpitations; visual disturbances; nausea and vomiting (possibly with colic and even bloody diarrhea); syncope (especially in the upright posture); air hunger and dyspnea, later followed by reduced ventilatory effort; diaphoresis, with the skin either flushed or cold and clammy; heart block and bradycardia; paralysis; coma; seizures and death. Laboratory determinations of serum levels of isosorbide mononitrate and its metabolites are not widely available, and such determinations have, in any event, no established role in the management of isosorbide mononitrate overdose. There are no data suggesting what dose of isosorbide mononitrate is likely to be life-threatening in humans. In rats and mice, there is significant lethality at oral doses of 1965 mg/kg and 2581 mg/kg, respectively. No data are available to suggest physiological maneuvers (e.g., maneuvers to change the pH of the urine) that might accelerate elimination of isosorbide mononitrate. Isosorbide mononitrate is significantly removed from the blood during hemodialysis. No specific antagonist to the vasodilator effects of isosorbide mononitrate is known, and no intervention has been subject to controlled study as a therapy of isosorbide mononitrate overdose. Because the hypotension associated with isosorbide mononitrate overdose is the result of venodilatation and arterial hypovolemia, prudent therapy in this situation should be directed toward an increase in central fluid volume. Passive elevation of the patient’s legs may be sufficient, but intravenous infusion of normal saline or similar fluid may also be necessary. The use of epinephrine or other arterial vasoconstrictors in this setting is likely to do more harm than good. In patients with renal disease or congestive heart failure, therapy resulting in central volume expansion is not without hazard. Treatment of isosorbide mononitrate overdose in these patients may be subtle and difficult, and invasive monitoring may be required. Methemoglobinemia Methemoglobinemia has been reported in patients receiving other organic nitrates, and it probably could also occur as a side effect of isosorbide mononitrate. Certainly nitrate ions liberated during metabolism of isosorbide mononitrate can oxidize hemoglobin into methemoglobin. Even in patients totally without cytochrome b5 reductase activity, however, and even assuming that the nitrate moiety of isosorbide mononitrate is quantitatively applied to oxidation of hemoglobin, about 2 mg/kg of isosorbide mononitrate should be required before any of these patients manifests clinically significant (≥10%) methemoglobinemia. In patients with normal reductase function, significant production of methemoglobin should require even larger doses of isosorbide mononitrate. In one study in which 36 patients received 2-4 weeks of continuous nitroglycerin therapy at 3.1 to 4.4 mg/hr (equivalent, in total administered dose of nitrate ions, to 7.8-11.1 mg of isosorbide mononitrate per hour), the average methemoglobin level measured was 0.2%; this was comparable to that observed in parallel patients who received placebo. Notwithstanding these observations, there are case reports of significant methemoglobinemia in association with moderate overdoses of organic nitrates. None of the affected patients had been thought to be unusually susceptible. Methemoglobin levels are available from most clinical laboratories. The diagnosis should be suspected in patients who exhibit signs of impaired oxygen delivery despite adequate cardiac output and adequate arterial p0 2 . Classically, methemoglobinemic blood is described as chocolate brown, without color change on exposure to air. When methemoglobinemia is diagnosed, the treatment of choice is methylene blue, 1-2 mg/kg intravenously."],"description":["DESCRIPTION Isosorbide mononitrate, an organic nitrate, is a vasodilator with effects on both arteries and veins. The empirical formula is C 6 H 9 NO 6 and the molecular weight is 191.14. The chemical name for Isosorbide mononitrate is 1,4:3,6-Dianhydro-D-glucitol 5-nitrate and the compound has the following structural formula: Isosorbide Mononitrate Tablets USP, for oral administration, are available in 10 mg and 20 mg tablets. Each tablet contains the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, povidone, magnesium stearate, polyvinyl alcohol, polyethylene glycol, titanium dioxide, and talc. The 20 mg tablets also contain D&C yellow #10 aluminum lake, FD&C yellow #6 aluminum lake, and FD&C blue #2 aluminum lake. FDA approved dissolution test specifications differ from USP. Stucture"],"precautions":["PRECAUTIONS General Severe hypotension, particularly with upright posture, may occur with even small doses of isosorbide mononitrate. This drug should therefore be used with caution in patients who may be volume depleted or who, for whatever reason, are already hypotensive. Hypotension induced by isosorbide mononitrate may be accompanied by paradoxical bradycardia and increased angina pectoris. Nitrate therapy may aggravate the angina caused by hypertrophic cardiomyopathy. In industrial workers who have had long-term exposure to unknown (presumably high) doses of organic nitrates, tolerance clearly occurs. Chest pain, acute myocardial infarction, and even sudden death have occurred during temporary withdrawal of nitrates from these workers, demonstrating the existence of true physical dependence. The importance of these observations to the routine, clinical use of oral isosorbide mononitrate is not known. Information for Patients Patients should be told that the antianginal efficacy of isosorbide mononitrate tablets can be maintained by carefully following the prescribed schedule of dosing (two doses taken seven hours apart). For most patients, this can be accomplished by taking the first dose on awakening and the second dose 7 hours later. As with other nitrates, daily headaches sometimes accompany treatment with isosorbide mononitrate. In patients who get these headaches, the headaches are a marker of the activity of the drug. Patients should resist the temptation to avoid headaches by altering the schedule of their treatment with isosorbide mononitrate, since loss of headache may be associated with simultaneous loss of antianginal efficacy. Aspirin and/or acetaminophen, on the other hand, often successfully relieve isosorbide mononitrate-induced headaches with no deleterious effect on isosorbide mononitrate’s antianginal efficacy. Treatment with isosorbide mononitrate may be associated with light-headedness on standing, especially just after rising from a recumbent or seated position. This effect may be more frequent in patients who have also consumed alcohol. Drug Interactions Concomitant use of isosorbide mononitrate with phosphodiesterase inhibitors in any form is contraindicated (see CONTRAINDICATIONS ). Concomitant use of isosorbide mononitrate with riociguat, a soluble guanylate cyclase stimulator, is contraindicated (see CONTRAINDICATIONS ). The vasodilating effects of isosorbide mononitrate may be additive with those of other vasodilators. Alcohol, in particular, has been found to exhibit additive effects of this variety. Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination. Dose adjustments of either class of agents may be necessary. Carcinogenesis, Mutagenesis, Impairment of Fertility No evidence of carcinogenicity was observed in rats exposed to isosorbide mononitrate in their diets at doses of up to 900 mg/kg/day for the first six months and 500 mg/kg/day for the remaining duration of a study in which males were dosed for up to 121 weeks and females were dosed for up to 137 weeks. No evidence of mutagenicity was seen in vitro in the Salmonella test (Ames test), in human peripheral lymphocytes, in Chinese hamster cells (V79) or, in vivo in the rat micronucleus test. In a study on the fertility and breeding capacity of two generations of rats, isosorbide mononitrate had no adverse effects on fertility or general reproductive performance with oral doses up to 120 mg/kg/day. A dose of 360 mg/kg/day was associated with increased mortality in treated males and females and a reduced fertility index. (See table at end of Pregnancy section for animal-to-human dosage comparisons.) Pregnancy Teratogenic Effects Reproduction studies performed in rats and rabbits at doses of up to 540 and 810 mg/kg/day, respectively, have revealed no evidence of harm to the fetus due to isosorbide mononitrate. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, isosorbide mononitrate should be used during pregnancy only if clearly needed. Nonteratogenic Effects Birth weights, neonatal survival and development, and incidence of stillbirths were adversely affected when pregnant rats were administered oral doses of 540 (but not 270) mg isosorbide mononitrate/kg/day during late gestation and lactation. This dose was associated with decreased maternal body weight gain and decreased maternal motor activity. Species Daily dose (mg/kg) Multiple of MRHD* Based on: Body Weight Body Surface Rabbit 810 1013 375 Rat 900 540 500 360 270 1125 675 625 450 338 195 117 108 78 59 Calculations assume a human weight of 50 kg and human body surface area of 1.46 m 2 , a rabbit weight of 2 kg and rabbit body surface area of 0.163 m 2 , and a rat weight of 150 g and rat body surface area of 0.025 m 2 . *Maximum recommended human dose (MRHD) is 20 mg bid. Nursing Mothers It is not known whether isosorbide mononitrate is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when isosorbide mononitrate is administered to a nursing woman. Pediatric Use Safety and effectiveness of isosorbide mononitrate in pediatric patients have not been established. Geriatric Use Clinical studies of isosorbide mononitrate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."],"how_supplied":["HOW SUPPLIED Isosorbide Mononitrate Tablets USP, 10 mg are white, round, film-coated tablets, scored on one side and debossed “ANI” over “252” on the other side. They are available in bottles of 100 tablets (NDC 62559-252-01). Isosorbide Mononitrate Tablets USP, 20 mg are yellow, round, film-coated tablets, scored on one side and debossed “ANI” over “253” on the other side. They are available in bottles of 100 tablets (NDC 62559-253-01). Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]. Keep tightly closed. Distributed by: ANI Pharmaceuticals, Inc. Baudette, MN 56623 10811 Rev 10/25 logo"],"geriatric_use":["Geriatric Use Clinical studies of isosorbide mononitrate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."],"pediatric_use":["Pediatric Use Safety and effectiveness of isosorbide mononitrate in pediatric patients have not been established."],"effective_time":"20260327","nursing_mothers":["Nursing Mothers It is not known whether isosorbide mononitrate is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when isosorbide mononitrate is administered to a nursing woman."],"pregnancy_table":["
SpeciesDaily dose (mg/kg)Multiple of MRHD* Based on:
Body WeightBody Surface
Rabbit8101013375
Rat900 540 500 360 2701125 675 625 450 338195 117 108 78 59
"],"clinical_studies":["Clinical Trials The acute and chronic antianginal efficacy of isosorbide mononitrate has been confirmed in clinical trials. The clinical efficacy of isosorbide mononitrate was studied in 21 stable angina pectoris patients. After single dose administration of isosorbide mononitrate , 20 mg, the exercise capacity was increased by 42.7% after one hour, 29.6% after 6 hours, and by 25% after eight hours when compared to placebo. Controlled trials of single doses of isosorbide mononitrate tablets have demonstrated that antianginal activity is present about 1 hour after dosing, with peak effect seen from 1-4 hours after dosing. In one multicenter placebo-controlled trial, isosorbide mononitrate was found to be safe and effective during acute and chronic (3 weeks) treatment of angina pectoris. Two hundred fourteen (214) patients were enrolled in the trial; 54 patients were randomized to receive placebo and 106 patients were randomized to receive 10 or 20 mg of isosorbide mononitrate twice daily seven hours apart. The largest effect of isosorbide mononitrate, compared to placebo, was on day one – dose one. Although 14 hours after the first dose of day 14, the increase in exercise tolerance due to isosorbide mononitrate was statistically significant, the increase was about half of that seen 2 hours after the first dose of day one. On day 21, two hours after the first dose the effect of isosorbide mononitrate was 60 to 70% of that seen on day one."],"pharmacodynamics":["Pharmacodynamics Dosing regimens for most chronically used drugs are designed to provide plasma concentrations that are continuously greater than a minimally effective concentration. This strategy is inappropriate for organic nitrates. Several well-controlled clinical trials have used exercise testing to assess the antianginal efficacy of continuously-delivered nitrates. In the large majority of these trials, active agents were indistinguishable from placebo after 24 hours (or less) of continuous therapy. Attempts to overcome tolerance by dose escalation, even to doses far in excess of those used acutely, have consistently failed. Only after nitrates have been absent from the body for several hours has their antianginal efficacy been restored. The drug-free interval sufficient to avoid tolerance to isosorbide mononitrate has not been completely defined. In the only regimen of twice-daily isosorbide mononitrate that has been shown to avoid development of tolerance, the two doses of isosorbide mononitrate tablets are given 7 hours apart, so there is a gap of 17 hours between the second dose of each day and the first dose of the next day. Taking account of the relatively long half-life of isosorbide mononitrate this result is consistent with those obtained for other organic nitrates. The asymmetric twice-daily regimen of isosorbide mononitrate tablets successfully avoided significant rebound/withdrawal effects. The incidence and magnitude of such phenomena have appeared, in studies of other nitrates, to be highly dependent upon the schedule of nitrate administration."],"pharmacokinetics":["Pharmacokinetics Isosorbide mononitrate is rapidly and completely absorbed from the gastrointestinal tract. In humans, isosorbide mononitrate is not subject to first pass metabolism in the liver. The absolute bioavailability of isosorbide mononitrate from isosorbide mononitrate tablets is nearly 100%. Peak plasma concentrations usually occur in about 30-60 minutes. Isosorbide mononitrate exhibits dose proportionality over the recommended dose range. Food does not significantly affect the absorption or bioavailability of isosorbide mononitrate. Metoprolol coadministration did not change the pharmacokinetics of isosorbide mononitrate. The volume of distribution is approximately 0.6 L/kg. Plasma protein binding of isosorbide mononitrate was found to be less than 5%. When radiolabelled isosorbide mononitrate was administered to humans in order to elucidate the metabolic fate, about half of the dose was found denitrated and renally excreted as isosorbide and sorbitol. One quarter of the dose was accounted for as conjugates of the parent drug in the urine. None of these metabolites are vasoactive. Only 2% of the dose was excreted as unchanged drug. The overall elimination half-life of isosorbide mononitrate is about 5 hours. The rate of clearance is the same in healthy young adults, in patients with various degrees of renal, hepatic or cardiac dysfunction and in the elderly. When radiolabelled isosorbide mononitrate was administered to humans, 93% of the dose was excreted within 48 hours into the urine. Renal excretion was virtually complete after 5 days; fecal excretion amounted to only 1% of the dose. Isosorbide mononitrate has no known effect on renal and hepatic function. In patients with varying degrees of renal failure, dosage adjustment does not appear necessary. In patients with liver cirrhosis, the pharmacokinetic parameters after a single dose of isosorbide mononitrate tablets were similar to the values found in healthy volunteers. Isosorbide mononitrate is significantly removed from the blood during hemodialysis; however , an additional dose to compensate for drug lost is not necessary. In patients undergoing continuous ambulatory peritoneal dialysis, blood levels are similar to patients not on dialysis."],"adverse_reactions":["ADVERSE REACTIONS Headache is the most frequent side effect and was the cause of 2% of all dropouts from controlled-clinical trials. Headache decreased in incidence after the first few days of therapy. The following table shows the frequency of adverse reactions observed in 1% or more of subjects in 6 placebo-controlled trials, conducted in the United States and abroad. The same table shows the frequency of withdrawal for these adverse reactions. In many cases the adverse reactions were of uncertain relation to drug treatment. Frequency Of Adverse Reactions (Discontinuations)* 6 Placebo-Controlled Studies Dose Placebo 5 mg 10 mg 20 mg Patients 160 54 52 159 Headache 6% (0%) 17% (0%) 13% (0%) 35% (5%) Fatigue 2% (0%) 0% (0%) 4% (0%) 1% (0%) Upper Respiratory Infection <1% (0%) 0% (0%) 4% (0%) 1% (0%) Pain <1% (0%) 4% (0%) 0% (0%) <1% (0%) Dizziness 1% (0%) 0% (0%) 0% (0%) 4% (0%) Nausea <1% (0%) 0% (0%) 0% (0%) 3% (2%) Increased Cough <1% (0%) 0% (0%) 2% (0%) <1% (0%) Rash 0% (0%) 2% (2%) 0% (0%) <1% (0%) Abdominal Pain <1% (0%) 0% (0%) 2% (0%) 0% (0%) Allergic Reaction 0% (0%) 0% (0%) 2% (0%) 0% (0%) Cardiovascular Disorder 0% (0%) 2% (0%) 0% (0%) 0% (0%) Chest Pain <1% (0%) 0% (0%) 2% (0%) <1% (0%) Diarrhea 0% (0%) 0% (0%) 2% (0%) 0% (0%) Flushing 0% (0%) 0% (0%) 2% (0%) 0% (0%) Emotional Lability 0% (0%) 2% (0%) 0% (0%) 0% (0%) Pruritus 1% (0%) 2% (2%) 0% (0%) 0% (0%) *Some individuals discontinued for multiple reasons. Other adverse reactions, each reported by fewer than 1% of exposed patients, and in many cases of uncertain relation to drug treatment, were: Cardiovascular: acute myocardial infarction, apoplexy, arrhythmias, bradycardia, edema, hypertension, hypotension, pallor, palpitations, tachycardia. Dermatologic: sweating. Gastrointestinal: anorexia, dry mouth, dyspepsia, thirst, vomiting, decreased weight. Genitourinary: prostatic disorder. Miscellaneous: amblyopia, back pain, bitter taste, muscle cramps, neck pain, paresthesia, susurrus aurium. Neurologic: anxiety, impaired concentration, depression, insomnia, nervousness, nightmares, restlessness, tremor, vertigo. Respiratory: asthma, dyspnea, sinusitis. Extremely rarely, ordinary doses of organic nitrates have caused methemoglobinemia in normal-seeming patients; for further discussion of its diagnosis and treatment see OVERDOSAGE . To report SUSPECTED ADVERSE REACTIONS, contact ANI Pharmaceuticals, Inc. at 1-855-204-1431 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."],"contraindications":["CONTRAINDICATIONS Isosorbide mononitrate is contraindicated in patients who are allergic to it. Do not use isosorbide mononitrate in patients who are taking certain drugs for erectile dysfunction (phosphodiesterase inhibitors), such as sildenafil, tadalafil, or vardenafil. Concomitant use can cause severe hypotension, syncope, or myocardial ischemia. Do not use isosorbide mononitrate in patients who are taking the soluble guanylate cyclase stimulator riociguat. Concomitant use can cause hypotension."],"drug_interactions":["Drug Interactions Concomitant use of isosorbide mononitrate with phosphodiesterase inhibitors in any form is contraindicated (see CONTRAINDICATIONS ). Concomitant use of isosorbide mononitrate with riociguat, a soluble guanylate cyclase stimulator, is contraindicated (see CONTRAINDICATIONS ). The vasodilating effects of isosorbide mononitrate may be additive with those of other vasodilators. Alcohol, in particular, has been found to exhibit additive effects of this variety. Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination. Dose adjustments of either class of agents may be necessary."],"precautions_table":["
SpeciesDaily dose (mg/kg)Multiple of MRHD* Based on:
Body WeightBody Surface
Rabbit8101013375
Rat900 540 500 360 2701125 675 625 450 338195 117 108 78 59
"],"general_precautions":["General Severe hypotension, particularly with upright posture, may occur with even small doses of isosorbide mononitrate. This drug should therefore be used with caution in patients who may be volume depleted or who, for whatever reason, are already hypotensive. Hypotension induced by isosorbide mononitrate may be accompanied by paradoxical bradycardia and increased angina pectoris. Nitrate therapy may aggravate the angina caused by hypertrophic cardiomyopathy. In industrial workers who have had long-term exposure to unknown (presumably high) doses of organic nitrates, tolerance clearly occurs. Chest pain, acute myocardial infarction, and even sudden death have occurred during temporary withdrawal of nitrates from these workers, demonstrating the existence of true physical dependence. The importance of these observations to the routine, clinical use of oral isosorbide mononitrate is not known."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Isosorbide mononitrate is the major active metabolite of isosorbide dinitrate (ISDN), and most of the clinical activity of the dinitrate is attributable to the mononitrate. The principal pharmacological action of isosorbide mononitrate is relaxation of vascular smooth muscle and consequent dilatation of peripheral arteries and veins, especially the latter. Dilation of the veins promotes peripheral pooling of blood and decreases venous return to the heart, thereby reducing left ventricular end-diastolic pressure and pulmonary capillary wedge pressure (preload). Arteriolar relaxation reduces systemic vascular resistance, systolic arterial pressure, and mean arterial pressure (afterload). Dilatation of the coronary arteries also occurs. The relative importance of preload reduction, afterload reduction and coronary dilatation remains undefined. Pharmacodynamics Dosing regimens for most chronically used drugs are designed to provide plasma concentrations that are continuously greater than a minimally effective concentration. This strategy is inappropriate for organic nitrates. Several well-controlled clinical trials have used exercise testing to assess the antianginal efficacy of continuously-delivered nitrates. In the large majority of these trials, active agents were indistinguishable from placebo after 24 hours (or less) of continuous therapy. Attempts to overcome tolerance by dose escalation, even to doses far in excess of those used acutely, have consistently failed. Only after nitrates have been absent from the body for several hours has their antianginal efficacy been restored. The drug-free interval sufficient to avoid tolerance to isosorbide mononitrate has not been completely defined. In the only regimen of twice-daily isosorbide mononitrate that has been shown to avoid development of tolerance, the two doses of isosorbide mononitrate tablets are given 7 hours apart, so there is a gap of 17 hours between the second dose of each day and the first dose of the next day. Taking account of the relatively long half-life of isosorbide mononitrate this result is consistent with those obtained for other organic nitrates. The asymmetric twice-daily regimen of isosorbide mononitrate tablets successfully avoided significant rebound/withdrawal effects. The incidence and magnitude of such phenomena have appeared, in studies of other nitrates, to be highly dependent upon the schedule of nitrate administration. Pharmacokinetics Isosorbide mononitrate is rapidly and completely absorbed from the gastrointestinal tract. In humans, isosorbide mononitrate is not subject to first pass metabolism in the liver. The absolute bioavailability of isosorbide mononitrate from isosorbide mononitrate tablets is nearly 100%. Peak plasma concentrations usually occur in about 30-60 minutes. Isosorbide mononitrate exhibits dose proportionality over the recommended dose range. Food does not significantly affect the absorption or bioavailability of isosorbide mononitrate. Metoprolol coadministration did not change the pharmacokinetics of isosorbide mononitrate. The volume of distribution is approximately 0.6 L/kg. Plasma protein binding of isosorbide mononitrate was found to be less than 5%. When radiolabelled isosorbide mononitrate was administered to humans in order to elucidate the metabolic fate, about half of the dose was found denitrated and renally excreted as isosorbide and sorbitol. One quarter of the dose was accounted for as conjugates of the parent drug in the urine. None of these metabolites are vasoactive. Only 2% of the dose was excreted as unchanged drug. The overall elimination half-life of isosorbide mononitrate is about 5 hours. The rate of clearance is the same in healthy young adults, in patients with various degrees of renal, hepatic or cardiac dysfunction and in the elderly. When radiolabelled isosorbide mononitrate was administered to humans, 93% of the dose was excreted within 48 hours into the urine. Renal excretion was virtually complete after 5 days; fecal excretion amounted to only 1% of the dose. Isosorbide mononitrate has no known effect on renal and hepatic function. In patients with varying degrees of renal failure, dosage adjustment does not appear necessary. In patients with liver cirrhosis, the pharmacokinetic parameters after a single dose of isosorbide mononitrate tablets were similar to the values found in healthy volunteers. Isosorbide mononitrate is significantly removed from the blood during hemodialysis; however , an additional dose to compensate for drug lost is not necessary. In patients undergoing continuous ambulatory peritoneal dialysis, blood levels are similar to patients not on dialysis. Clinical Trials The acute and chronic antianginal efficacy of isosorbide mononitrate has been confirmed in clinical trials. The clinical efficacy of isosorbide mononitrate was studied in 21 stable angina pectoris patients. After single dose administration of isosorbide mononitrate , 20 mg, the exercise capacity was increased by 42.7% after one hour, 29.6% after 6 hours, and by 25% after eight hours when compared to placebo. Controlled trials of single doses of isosorbide mononitrate tablets have demonstrated that antianginal activity is present about 1 hour after dosing, with peak effect seen from 1-4 hours after dosing. In one multicenter placebo-controlled trial, isosorbide mononitrate was found to be safe and effective during acute and chronic (3 weeks) treatment of angina pectoris. Two hundred fourteen (214) patients were enrolled in the trial; 54 patients were randomized to receive placebo and 106 patients were randomized to receive 10 or 20 mg of isosorbide mononitrate twice daily seven hours apart. The largest effect of isosorbide mononitrate, compared to placebo, was on day one – dose one. Although 14 hours after the first dose of day 14, the increase in exercise tolerance due to isosorbide mononitrate was statistically significant, the increase was about half of that seen 2 hours after the first dose of day one. On day 21, two hours after the first dose the effect of isosorbide mononitrate was 60 to 70% of that seen on day one."],"indications_and_usage":["INDICATIONS AND USAGE Isosorbide Mononitrate Tablets USP are indicated for the prevention and treatment of angina pectoris due to coronary artery disease. The onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode."],"adverse_reactions_table":["
Frequency Of Adverse Reactions(Discontinuations)*
6 Placebo-Controlled Studies
DosePlacebo5 mg10 mg20 mg
Patients1605452159
Headache6% (0%)17% (0%)13% (0%)35% (5%)
Fatigue2% (0%)0% (0%)4% (0%)1% (0%)
Upper Respiratory Infection<1% (0%)0% (0%)4% (0%)1% (0%)
Pain<1% (0%)4% (0%)0% (0%)<1% (0%)
Dizziness1% (0%)0% (0%)0% (0%)4% (0%)
Nausea<1% (0%)0% (0%)0% (0%)3% (2%)
Increased Cough<1% (0%)0% (0%)2% (0%)<1% (0%)
Rash0% (0%)2% (2%)0% (0%)<1% (0%)
Abdominal Pain<1% (0%)0% (0%)2% (0%)0% (0%)
Allergic Reaction0% (0%)0% (0%)2% (0%)0% (0%)
Cardiovascular Disorder0% (0%)2% (0%)0% (0%)0% (0%)
Chest Pain<1% (0%)0% (0%)2% (0%)<1% (0%)
Diarrhea0% (0%)0% (0%)2% (0%)0% (0%)
Flushing0% (0%)0% (0%)2% (0%)0% (0%)
Emotional Lability0% (0%)2% (0%)0% (0%)0% (0%)
Pruritus1% (0%)2% (2%)0% (0%)0% (0%)
*Some individuals discontinued for multiple reasons.
"],"information_for_patients":["Information for Patients Patients should be told that the antianginal efficacy of isosorbide mononitrate tablets can be maintained by carefully following the prescribed schedule of dosing (two doses taken seven hours apart). For most patients, this can be accomplished by taking the first dose on awakening and the second dose 7 hours later. As with other nitrates, daily headaches sometimes accompany treatment with isosorbide mononitrate. In patients who get these headaches, the headaches are a marker of the activity of the drug. Patients should resist the temptation to avoid headaches by altering the schedule of their treatment with isosorbide mononitrate, since loss of headache may be associated with simultaneous loss of antianginal efficacy. Aspirin and/or acetaminophen, on the other hand, often successfully relieve isosorbide mononitrate-induced headaches with no deleterious effect on isosorbide mononitrate’s antianginal efficacy. Treatment with isosorbide mononitrate may be associated with light-headedness on standing, especially just after rising from a recumbent or seated position. This effect may be more frequent in patients who have also consumed alcohol."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION The recommended regimen of isosorbide mononitrate tablets is 20 mg twice daily, with the doses seven hours apart. A starting dose of 5 mg (½ tablet of the 10 mg dosing strength) might be appropriate for persons of particularly small stature but should be increased to at least 10 mg by the second or third day of therapy. Dosage adjustments are not necessary for elderly patients or patients with altered hepatic or renal function. As noted above ( CLINICAL PHARMACOLOGY ), multiple studies of organic nitrates have shown that maintenance of continuous 24-hour plasma levels results in refractory tolerance. The asymmetric (2 doses, 7 hours apart) dosing regimen for isosorbide mononitrate tablets provides a daily nitrate-free interval to minimize the development of tolerance. As also noted under CLINICAL PHARMACOLOGY , well-controlled studies have shown that tolerance to isosorbide mononitrate tablets occurs to some extent when using the twice-daily regimen in which the two doses are given seven hours apart. This regimen has been shown to have antianginal efficacy beginning one hour after the first dose and lasting at least seven hours after the second dose. The duration (if any) of antianginal activity beyond fourteen hours has not been studied. In clinical trials, isosorbide mononitrate has been administered in a variety of regimens and doses. Doses above 20 mg twice a day (with the doses seven hours apart) have not been adequately studied. Doses of 5 mg twice a day are clearly effective (effectiveness based on exercise tolerance) for only the first day of a twice-a-day (with doses 7 hours apart) regimen."],"spl_product_data_elements":["Isosorbide Mononitrate Isosorbide Mononitrate ISOSORBIDE MONONITRATE ISOSORBIDE MONONITRATE LACTOSE MONOHYDRATE MICROCRYSTALLINE CELLULOSE 101 SODIUM STARCH GLYCOLATE TYPE A POTATO POVIDONE K30 MAGNESIUM STEARATE POLYVINYL ALCOHOL, UNSPECIFIED POLYETHYLENE GLYCOL, UNSPECIFIED TITANIUM DIOXIDE TALC ANI;252 Isosorbide Mononitrate Isosorbide Mononitrate ISOSORBIDE MONONITRATE ISOSORBIDE MONONITRATE LACTOSE MONOHYDRATE MICROCRYSTALLINE CELLULOSE 101 SODIUM STARCH GLYCOLATE TYPE A POTATO POVIDONE K30 MAGNESIUM STEARATE POLYVINYL ALCOHOL, UNSPECIFIED POLYETHYLENE GLYCOL, UNSPECIFIED TITANIUM DIOXIDE TALC D&C YELLOW NO. 10 ALUMINUM LAKE FD&C YELLOW NO. 6 FD&C BLUE NO. 2 ANI;253"],"package_label_principal_display_panel":["PACKAGE/LABEL PRINCIPAL DISPLAY PANEL NDC 62559- 252 -01 Isosorbide Mononitrate Tablets USP, 10 mg Rx only 100 Tablets 10mg-label","PACKAGE/LABEL PRINCIPAL DISPLAY PANEL NDC 62559- 253 -01 Isosorbide Mononitrate Tablets USP, 20 mg Rx only 100 Tablets 20mg-label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility No evidence of carcinogenicity was observed in rats exposed to isosorbide mononitrate in their diets at doses of up to 900 mg/kg/day for the first six months and 500 mg/kg/day for the remaining duration of a study in which males were dosed for up to 121 weeks and females were dosed for up to 137 weeks. No evidence of mutagenicity was seen in vitro in the Salmonella test (Ames test), in human peripheral lymphocytes, in Chinese hamster cells (V79) or, in vivo in the rat micronucleus test. In a study on the fertility and breeding capacity of two generations of rats, isosorbide mononitrate had no adverse effects on fertility or general reproductive performance with oral doses up to 120 mg/kg/day. A dose of 360 mg/kg/day was associated with increased mortality in treated males and females and a reduced fertility index. (See table at end of Pregnancy section for animal-to-human dosage comparisons.)"]},"tags":[{"label":"isosorbide","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Ocular hypertension","category":"indication"},{"label":"Alcon","category":"company"},{"label":"Approved 1970s","category":"decade"},{"label":"Diuretics","category":"pharmacology"},{"label":"Diuretics, Osmotic","category":"pharmacology"},{"label":"Natriuretic Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":467.407,"date":"","count":133,"signal":"Cardiospasm","source":"DrugCentral FAERS","actionTaken":"Reported 133 times (LLR=467)"},{"llr":446.253,"date":"","count":132,"signal":"Palmoplantar keratoderma","source":"DrugCentral FAERS","actionTaken":"Reported 132 times (LLR=446)"},{"llr":414.115,"date":"","count":131,"signal":"Pruritus genital","source":"DrugCentral FAERS","actionTaken":"Reported 131 times (LLR=414)"},{"llr":412.703,"date":"","count":469,"signal":"Myocardial infarction","source":"DrugCentral FAERS","actionTaken":"Reported 469 times (LLR=413)"},{"llr":409.35,"date":"","count":131,"signal":"Sleep terror","source":"DrugCentral FAERS","actionTaken":"Reported 131 times (LLR=409)"},{"llr":377.039,"date":"","count":139,"signal":"Carotid artery occlusion","source":"DrugCentral FAERS","actionTaken":"Reported 139 times (LLR=377)"},{"llr":375.18,"date":"","count":136,"signal":"Atrial tachycardia","source":"DrugCentral FAERS","actionTaken":"Reported 136 times (LLR=375)"},{"llr":366.42,"date":"","count":135,"signal":"Tension headache","source":"DrugCentral FAERS","actionTaken":"Reported 135 times (LLR=366)"},{"llr":326.277,"date":"","count":134,"signal":"Anosmia","source":"DrugCentral FAERS","actionTaken":"Reported 134 times (LLR=326)"},{"llr":319.157,"date":"","count":173,"signal":"Subarachnoid haemorrhage","source":"DrugCentral FAERS","actionTaken":"Reported 173 times (LLR=319)"},{"llr":301.852,"date":"","count":86,"signal":"Immunisation","source":"DrugCentral FAERS","actionTaken":"Reported 86 times (LLR=302)"},{"llr":297.378,"date":"","count":135,"signal":"Facial pain","source":"DrugCentral FAERS","actionTaken":"Reported 135 times (LLR=297)"},{"llr":270.651,"date":"","count":333,"signal":"Cardiac failure congestive","source":"DrugCentral FAERS","actionTaken":"Reported 333 times (LLR=271)"},{"llr":264.523,"date":"","count":133,"signal":"Pain of skin","source":"DrugCentral FAERS","actionTaken":"Reported 133 times (LLR=265)"},{"llr":241.127,"date":"","count":176,"signal":"Ventricular tachycardia","source":"DrugCentral FAERS","actionTaken":"Reported 176 times (LLR=241)"}],"drugInteractions":[{"url":"/drug/sildenafil","drug":"sildenafil","action":"Avoid combination","effect":"May interact with Sildenafil Citrate","source":"DrugCentral","drugSlug":"sildenafil"},{"url":"/drug/tadalafil","drug":"tadalafil","action":"Avoid combination","effect":"May interact with Tadalafil","source":"DrugCentral","drugSlug":"tadalafil"},{"url":"/drug/vardenafil","drug":"vardenafil","action":"Avoid combination","effect":"May interact with Vardenafil","source":"DrugCentral","drugSlug":"vardenafil"}],"commonSideEffects":[{"effect":"Cardiospasm","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Palmoplantar keratoderma","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Pruritus genital","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Myocardial infarction","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Sleep terror","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Carotid artery occlusion","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Atrial tachycardia","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Tension headache","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Anosmia","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Subarachnoid haemorrhage","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Immunisation","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Facial pain","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Cardiac failure congestive","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Pain of skin","drugRate":"","severity":"common","_validated":false,"_confidence":0.3},{"effect":"Ventricular tachycardia","drugRate":"","severity":"common","_validated":false,"_confidence":0.3}]},"trials":[],"aliases":[],"company":"Novartis","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ISOSORBIDE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:28:19.153395+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Isosorbide","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T03:28:26.667210+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:28:24.920891+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ISOSORBIDE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:28:25.518324+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:28:17.972940+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:28:17.972970+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:28:17.972976+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200660/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:28:26.248299+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA075147","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:28:17.972979+00:00"}},"allNames":"isobide","offLabel":[],"synonyms":["isosorbide","(+)-D-Isosorbide","isobide"],"timeline":[{"date":"1974-01-30","type":"positive","source":"DrugCentral","milestone":"FDA approval (Alcon)"}],"aiSummary":"Isobide, also known as Isosorbide, is a small molecule drug originally developed by Alcon and currently owned by the same company. It is classified under the isosorbide drug class and was FDA approved in 1974 for the treatment of ocular hypertension. As an off-patent medication with no active Orange Book patents, Isobide is available as a branded product. Key safety considerations for Isobide include its potential effects on intraocular pressure, which should be closely monitored by healthcare professionals. The commercial status of Isobide is branded, with no generic manufacturers available.","approvals":[{"date":"1974-01-30","orphan":false,"company":"ALCON","regulator":"FDA"}],"brandName":"Isobide","ecosystem":[{"indication":"Ocular hypertension","otherDrugs":[{"name":"betaxolol","slug":"betaxolol","company":"Alcon"},{"name":"bimatoprost","slug":"bimatoprost","company":""},{"name":"brimonidine","slug":"brimonidine","company":""},{"name":"brinzolamide","slug":"brinzolamide","company":"Alcon Pharms Ltd"}],"globalPrevalence":1280000000}],"mechanism":{"modality":"Small Molecule","drugClass":"Nitrate Vasodilator [EPC]","explanation":"","oneSentence":"","technicalDetail":"Isosorbide is a carbonic anhydrase inhibitor that decreases the production of aqueous humor in the eye, thereby reducing intraocular pressure."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Isosorbide","title":"Isosorbide","extract":"Isosorbide is a bicyclic chemical compound from the group of diols and the oxygen-containing heterocycles, containing two fused furan rings. The starting material for isosorbide is D-sorbitol, which is obtained by catalytic hydrogenation of D-glucose, which is in turn produced by hydrolysis of starch. Isosorbide is discussed as a plant-based platform chemical from which biodegradable derivatives of various functionality can be obtained."},"commercial":{"launchDate":"1974","_launchSource":"DrugCentral (FDA 1974-01-30, ALCON)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1501","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ISOSORBIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ISOSORBIDE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Isosorbide","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T12:11:23.462042","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:28:29.482193+00:00","fieldsConflicting":16,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"isosorbide","indications":{"approved":[{"name":"Ocular hypertension","source":"DrugCentral","snomedId":4210003,"regulator":"FDA","usPrevalence":119900000,"globalPrevalence":1280000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[],"trialDetails":[{"nctId":"NCT02627196","phase":"NA","title":"Baroreflex Activation Therapy for Heart Failure","status":"COMPLETED","sponsor":"CVRx, Inc.","startDate":"2016-04-19","conditions":["Heart Failure"],"enrollment":1090,"completionDate":"2023-10"},{"nctId":"NCT07456852","phase":"PHASE1,PHASE2","title":"Vasodilator Therapy With Isosorbide Mononitrate or Diltiazem to Reduce Vasotoxicity in Patients With Gastrointestinal Cancer Receiving Fluoropyrimidine Therapy","status":"NOT_YET_RECRUITING","sponsor":"Mayo Clinic","startDate":"2026-03-31","conditions":["Malignant Digestive System Neoplasm"],"enrollment":60,"completionDate":"2030-03-31"},{"nctId":"NCT03514108","phase":"PHASE4","title":"DANHEART (H-HeFT and Met-HeFT)","status":"COMPLETED","sponsor":"Henrik Wiggers","startDate":"2018-03-01","conditions":["Heart Failure","Diabetes"],"enrollment":1100,"completionDate":"2025-12-31"},{"nctId":"NCT03564327","phase":"NA","title":"Clinical Prognosis of Patients With Atrial Fibrillation During Radiofrequency Ablation","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2019-02-14","conditions":["Atrial Fibrillation"],"enrollment":175,"completionDate":"2024-09-10"},{"nctId":"NCT00930618","phase":"PHASE3","title":"Reduction of Cesareans by Nitric Oxide (NO) Donors in Post Term Pregnancies","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2009-06","conditions":["Prolonged Pregnancy","Nulliparity"],"enrollment":1409,"completionDate":"2014-04"},{"nctId":"NCT07252544","phase":"PHASE3","title":"Isosorbide Mononitrate and Butylphthalide to Reduce the Risk of Disability in Patients With Acute Lacunar Stroke (IMPACT)","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-12-01","conditions":["Stroke, Lacunar","Stroke, Acute Ischemic","Cerebral Small Vessel Diseases"],"enrollment":3156,"completionDate":"2028-02-29"},{"nctId":"NCT00262470","phase":"PHASE1,PHASE2","title":"Treatment of Orthostatic Intolerance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Satish R. Raj","startDate":"1997-04","conditions":["Tachycardia","Chronic Orthostatic Intolerance"],"enrollment":150,"completionDate":"2029-12"},{"nctId":"NCT06730945","phase":"PHASE4","title":"Effect of Oral Isosorbide Mononitrate Plus Amlodipine Antispasm Therapy on Outcomes of Radial Artery Grafts After CABG","status":"WITHDRAWN","sponsor":"Ruijin Hospital","startDate":"2025-06","conditions":["Coronary Artery Bypass Graft Surgery (CABG)","Radial Artery Grafts","Graft Failure"],"enrollment":0,"completionDate":"2030-12"},{"nctId":"NCT07121634","phase":"NA","title":"Cervical Ripening With Misoprostol vs Isosorbide Mononitrate ; A Parallel -Arm Randomized Controlled Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Raid M. Al-Ani","startDate":"2024-01-01","conditions":["Cervical Ripening"],"enrollment":80,"completionDate":"2026-08-31"},{"nctId":"NCT01471834","phase":"NA","title":"Verification of the Efficacy and Safety of the BAROSTIM NEO System in the Treatment of Drug Resistant Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"CVRx, Inc.","startDate":"2011-06","conditions":["High Blood Pressure"],"enrollment":40,"completionDate":"2026-08"},{"nctId":"NCT06726109","phase":"","title":"The FOCUS-ADHF Registry","status":"RECRUITING","sponsor":"ASL Città di Torino","startDate":"2025-04-27","conditions":["Acute Heart Failure With Reduced Ejection Fraction","Decompensation; Heart, Congestive","Regurgitation, Mitral"],"enrollment":600,"completionDate":"2030-08"},{"nctId":"NCT06715007","phase":"","title":"Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-12-20","conditions":["Stroke, Ischemic","Small Vessel Cerebrovascular Disease","White Matter Hyperintensity"],"enrollment":300,"completionDate":"2026-01-20"},{"nctId":"NCT06765993","phase":"PHASE2,PHASE3","title":"Efficacy and Safety of Isosorbide Oral Solution in Patients With Meniere's Disease","status":"NOT_YET_RECRUITING","sponsor":"Lunan Better Pharmaceutical Co., LTD.","startDate":"2024-12-30","conditions":["Meniere´s Disease"],"enrollment":234,"completionDate":"2027-12-30"},{"nctId":"NCT05276219","phase":"PHASE4","title":"Optimized Treatment of Pulmonary Edema or Congestion","status":"RECRUITING","sponsor":"Johannes Grand","startDate":"2023-09-14","conditions":["Pulmonary Edema","Congestive Heart Failure","Acute Heart Failure"],"enrollment":1104,"completionDate":"2026-12-31"},{"nctId":"NCT04310995","phase":"PHASE4","title":"Different Anti-Spastic Therapy Strategies After CABG Using Radial Artery Grafts","status":"COMPLETED","sponsor":"Ruijin Hospital","startDate":"2020-06-02","conditions":["Coronary Artery Bypass Graft","Radial Artery Grafts","Antispastic Therapy","Pilot Study"],"enrollment":150,"completionDate":"2023-06-28"},{"nctId":"NCT03451591","phase":"PHASE2,PHASE3","title":"LACunar Intervention (LACI-2) Trial-2","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2018-01-08","conditions":["Cerebral Small Vessel Diseases","Stroke, Lacunar"],"enrollment":363,"completionDate":"2022-08-11"},{"nctId":"NCT06496074","phase":"","title":"Heart Rate Variation in Females Predicts Tilt Test Results","status":"ACTIVE_NOT_RECRUITING","sponsor":"Federal University of Piaui","startDate":"2024-07-02","conditions":["Syncope, Vasovagal"],"enrollment":149,"completionDate":"2025-07-02"},{"nctId":"NCT03544606","phase":"PHASE4","title":"Nitric Oxide Donor Isosorbide Mono Nitrate for Cervical Ripening in Induction of Labor","status":"COMPLETED","sponsor":"ahmed nagy shaker ramadan","startDate":"2023-12-01","conditions":["Induction of Labor Affected Fetus / Newborn"],"enrollment":160,"completionDate":"2024-06-30"},{"nctId":"NCT04317846","phase":"NA","title":"Transradial Evaluation Study of Diameter Increase After Vasodilatory Drugs Administration.","status":"COMPLETED","sponsor":"University of Lausanne Hospitals","startDate":"2021-03-22","conditions":["Arterial Spasm","Coronary Artery Disease"],"enrollment":165,"completionDate":"2024-06-30"},{"nctId":"NCT02573051","phase":"PHASE2","title":"Termination Of Anembryonic Pregnancy","status":"WITHDRAWN","sponsor":"Assiut University","startDate":"2015-06","conditions":["Missed Abortion"],"enrollment":0,"completionDate":"2015-12-01"},{"nctId":"NCT06400784","phase":"PHASE4","title":"Hypertensive Heart Failure Treatment in SSA","status":"COMPLETED","sponsor":"University of Abuja","startDate":"2022-03-25","conditions":["A Feasibility Study on Hypertensive Heart Failure Treatment"],"enrollment":50,"completionDate":"2024-03-26"},{"nctId":"NCT02870985","phase":"NA","title":"BIOTRONIK Orsiro Pre-Marketing Registration","status":"COMPLETED","sponsor":"Biotronik (Beijing) Medical Device Ltd.","startDate":"2015-07-14","conditions":["Coronary Artery Disease"],"enrollment":440,"completionDate":"2021-12"},{"nctId":"NCT06218199","phase":"PHASE4","title":"Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts","status":"RECRUITING","sponsor":"Heart Center Research, LLC","startDate":"2021-07-08","conditions":["Heart Failure, Congestive"],"enrollment":80,"completionDate":"2026-12-31"},{"nctId":"NCT02305095","phase":"","title":"Genomic Response Analysis of Heart Failure Therapy in African Americans","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2015-05-01","conditions":["Heart Failure"],"enrollment":225,"completionDate":"2022-09-30"},{"nctId":"NCT05688735","phase":"NA","title":"Assessment of the Effect of Coconut and Sunflower Seed Oil Derived Isosorbide Diseters and Colloidial Oatmeal","status":"UNKNOWN","sponsor":"Integrative Skin Science and Research","startDate":"2023-04-20","conditions":["Atopic Dermatitis"],"enrollment":40,"completionDate":"2024-03-31"},{"nctId":"NCT05800938","phase":"PHASE4","title":"The Effect of Oral Isosorbide Mononitrate Therapy on Umbilical Artery Doppler Resistance Index in Pregnancies With Intrauterine Growth Restriction: Prospective Randomized Control Trial","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-06-08","conditions":["Intrauterine Growth Restriction"],"enrollment":46,"completionDate":"2022-12-06"},{"nctId":"NCT02649998","phase":"NA","title":"Short-term Efficacy of Furosemide, Isosorbide Dinitrate and Their Combination in ADHF","status":"WITHDRAWN","sponsor":"Chinese University of Hong Kong","startDate":"2017-01","conditions":["Heart Decompensation"],"enrollment":0,"completionDate":"2022-06"},{"nctId":"NCT05671250","phase":"PHASE2","title":"Bioactive Smart Dressings for Diabetic Foot Ulcers: Randomized Controlled Trial","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2021-07-15","conditions":["Diabetic Foot Ulcer"],"enrollment":30,"completionDate":"2023-01-01"},{"nctId":"NCT04831892","phase":"NA","title":"The Effect of Isosorbide Diesters Based Moisturizer on Skin Health","status":"COMPLETED","sponsor":"Integrative Skin Science and Research","startDate":"2021-04-12","conditions":["Atopic Dermatitis"],"enrollment":34,"completionDate":"2022-04-30"},{"nctId":"NCT02135315","phase":"NA","title":"Intensive Arterial Pressure Control in Acute Coronary Syndrome","status":"COMPLETED","sponsor":"University of Monastir","startDate":"2014-03","conditions":["Acute Coronary Syndrome"],"enrollment":1500,"completionDate":"2020-12-31"},{"nctId":"NCT04051957","phase":"PHASE2","title":"Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury","status":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2019-09-26","conditions":["Kidney Injury","Proteinuria","Hypertension"],"enrollment":9,"completionDate":"2021-02-12"},{"nctId":"NCT01516346","phase":"PHASE2","title":"Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction","status":"COMPLETED","sponsor":"Corporal Michael J. Crescenz VA Medical Center","startDate":"2012-01","conditions":["Heart Failure","Congestive Heart Failure"],"enrollment":44,"completionDate":"2017-08-18"},{"nctId":"NCT05341856","phase":"EARLY_PHASE1","title":"Uterine Artery Doppler Changes After Vaginal Administration of Isosorbide Mononitrate In Patients With URPL","status":"UNKNOWN","sponsor":"Al-Azhar University","startDate":"2022-05-01","conditions":["Recurrent Pregnancy Loss"],"enrollment":60,"completionDate":"2022-09"},{"nctId":"NCT03011775","phase":"PHASE4","title":"Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease","status":"COMPLETED","sponsor":"Ukrainian Medical Stomatological Academy","startDate":"2012-11","conditions":["Adverse Effect","Atherosclerosis, Coronary","Insulin Resistance Syndrome"],"enrollment":43,"completionDate":"2015-09"},{"nctId":"NCT00943852","phase":"PHASE1","title":"The Effect of Losartan and Losartan Plus Isosorbide Mononitrate on Central Blood Pressure Measurements (0954-317)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-08","conditions":["Hypertension"],"enrollment":13,"completionDate":"2006-12"},{"nctId":"NCT04538534","phase":"PHASE3","title":"Nicardipine to Avoid Spasm in Trans Radial Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Pr. Semir Nouira","startDate":"2020-11-01","conditions":["Spasm Artery"],"enrollment":1500,"completionDate":"2022-02-01"},{"nctId":"NCT03171480","phase":"PHASE4","title":"Use of Nitrous Oxide Donor for Labor Induction in Women With PreEclampsia","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2017-10-30","conditions":["Preeclampsia","Labor, Premature"],"enrollment":176,"completionDate":"2020-07-01"},{"nctId":"NCT03255512","phase":"PHASE1","title":"Vericiguat Drug-drug Interaction Study With Isosorbite Mononitrate in Stable Coronary Artery Disease Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-08-17","conditions":["Coronary Artery Disease"],"enrollment":41,"completionDate":"2018-03-23"},{"nctId":"NCT04297241","phase":"PHASE2","title":"Nitrate Effect on Exercise Capacitance","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2019-12-12","conditions":["Fontan"],"enrollment":20,"completionDate":"2021-05-03"},{"nctId":"NCT04981457","phase":"PHASE1","title":"Comparative Study Between Combined Vaginal Misoprostol","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2021-03-02","conditions":["Missed Abortion"],"enrollment":60,"completionDate":"2021-10"},{"nctId":"NCT04191681","phase":"PHASE4","title":"Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study","status":"RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2019-11-08","conditions":["Stage D Heart Failure"],"enrollment":50,"completionDate":"2022-12"},{"nctId":"NCT02045459","phase":"NA","title":"Microvascular Disease Exercise Trial","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2014-05","conditions":["Coronary Microvascular Disease"],"enrollment":79,"completionDate":"2021-05-17"},{"nctId":"NCT02228408","phase":"PHASE4","title":"Safety and Cardiovascular Efficacy of Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2017-08-28","conditions":["Chronic Hemodialysis (ESRD)"],"enrollment":17,"completionDate":"2019-05-07"},{"nctId":"NCT04218760","phase":"NA","title":"Multiomics After Headache Provocation of People Who Are Unable to Have Headache","status":"COMPLETED","sponsor":"Danish Headache Center","startDate":"2019-10-10","conditions":["Headache","Healthy"],"enrollment":58,"completionDate":"2020-03-12"},{"nctId":"NCT04217668","phase":"NA","title":"Headache Provocation of People Who Are Unable to Have Headache","status":"COMPLETED","sponsor":"Danish Headache Center","startDate":"2019-12-02","conditions":["Headache","Healthy"],"enrollment":58,"completionDate":"2020-03-12"},{"nctId":"NCT01270139","phase":"NA","title":"Plasmonic Nanophotothermal Therapy of Atherosclerosis","status":"COMPLETED","sponsor":"Ural State Medical University","startDate":"2007-04-01","conditions":["Stable Angina","Heart Failure","Atherosclerosis","Multivessel Coronary Artery Disease"],"enrollment":180,"completionDate":"2016-08-01"},{"nctId":"NCT04729088","phase":"PHASE1","title":"Pharmacokinetics Trial of Isosorbide Mononitrate 0.5% Gel for Intra Anal Application in Healthy Subjects","status":"WITHDRAWN","sponsor":"Biolab Sanus Farmaceutica","startDate":"2020-12-20","conditions":["Pharmacokinetics","Healthy Subjects"],"enrollment":0,"completionDate":"2020-12-20"},{"nctId":"NCT00143195","phase":"PHASE4","title":"Amlodipine vs Nitrates Study in Patients With Chronic Stable Angina","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2001-04","conditions":["Myocardial Ischemia"],"enrollment":200,"completionDate":"2005-01"},{"nctId":"NCT04661709","phase":"PHASE4","title":"Efficacy and Safety of Wen Xin Granules for the Treatment of Unstable Angina Pectoris","status":"UNKNOWN","sponsor":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","startDate":"2021-03-01","conditions":["Coronary Heart Disease","Unstable Angina","Chinese Herbal Medicine"],"enrollment":502,"completionDate":"2023-06-01"},{"nctId":"NCT04312048","phase":"PHASE3","title":"the Effect of Isosorbide Mononitrate in Reducing Pain During Cooper Intrauterine Device Insertion","status":"COMPLETED","sponsor":"Cairo University","startDate":"2020-04-15","conditions":["IUD Insertion Pain"],"enrollment":110,"completionDate":"2020-11-30"},{"nctId":"NCT02789033","phase":"PHASE3","title":"Efficacy of the Combination of Isosorbide Dinitrate Spray and Chitosan in Diabetic Foot Ulcers","status":"COMPLETED","sponsor":"University of Guadalajara","startDate":"2015-06","conditions":["Diabetic Foot Ulcers"],"enrollment":68,"completionDate":"2015-08"},{"nctId":"NCT04425993","phase":"NA","title":"Rectal Indomethacin Versus Rectal Indomethacin and Sublingual Nitrate for PEP Prevention","status":"UNKNOWN","sponsor":"Air Force Military Medical University, China","startDate":"2020-07-01","conditions":["Post-ERCP Acute Pancreatitis"],"enrollment":2700,"completionDate":"2022-12-30"},{"nctId":"NCT04206865","phase":"PHASE4","title":"Comparison of ARNI to Alternate Oral Vasodilator Therapies in Patients With Low Cardiac Output","status":"WITHDRAWN","sponsor":"The Cleveland Clinic","startDate":"2019-11-25","conditions":["Cardiogenic Shock"],"enrollment":0,"completionDate":"2020-09-10"},{"nctId":"NCT04482881","phase":"EARLY_PHASE1","title":"Isosorbide Mononitrate in Induction of Labour","status":"UNKNOWN","sponsor":"Aljazeera Hospital","startDate":"2020-07-21","conditions":["Labor Fast"],"enrollment":130,"completionDate":"2020-09-25"},{"nctId":"NCT03665779","phase":"PHASE3","title":"Nitric Oxide Donor Isosorbide Mono Nitrate for Induction of Labor With Pre-labor Rupture of Membranes","status":"COMPLETED","sponsor":"ahmed nagy shaker ramadan","startDate":"2018-08-01","conditions":["Induction of Labor Affected Fetus / Newborn","Rupture of Membranes Prior to Onset of Labor"],"enrollment":140,"completionDate":"2019-05-01"},{"nctId":"NCT04311658","phase":"PHASE3","title":"Safety and Efficacy of the Effect of Isosorbide Mononitrate in Reducing Pain During Levonorgestrel-releasing Intrauterine Device Insertion","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2020-03-30","conditions":["Contraception"],"enrollment":88,"completionDate":"2020-07-05"},{"nctId":"NCT04253704","phase":"PHASE1,PHASE2","title":"Effects of 2% IDL Lotion on Skin Hydration and Transepidermal Water Loss in Females With Dry Skin","status":"COMPLETED","sponsor":"Shyla Cantor","startDate":"2017-02-13","conditions":["Xerosis Cutis"],"enrollment":16,"completionDate":"2017-03-03"},{"nctId":"NCT03799133","phase":"NA","title":"Safety and Efficacy of the Gastric Reactance (XL) in Patients Post-operated of Elective Cardiac Surgery","status":"COMPLETED","sponsor":"Critical Perfusion Inc.","startDate":"2018-09-26","conditions":["Cardiac Failure","Ventricular Dysfunction","Valvular Heart Disease"],"enrollment":38,"completionDate":"2019-12-28"},{"nctId":"NCT02011620","phase":"PHASE4","title":"Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus","status":"WITHDRAWN","sponsor":"Tameside Hospital NHS Foundation Trust","startDate":"2014-10","conditions":["Endothelial Dysfunction","Bone Disease"],"enrollment":0,"completionDate":"2014-12"},{"nctId":"NCT01720160","phase":"NA","title":"BAROSTIM® Hope for Heart Failure Study","status":"UNKNOWN","sponsor":"CVRx, Inc.","startDate":"2012-11","conditions":["Heart Failure"],"enrollment":98,"completionDate":"2021-03"},{"nctId":"NCT03854383","phase":"PHASE2","title":"Using Isosorbide Mononitrate in Reducing Time in Induction of Labor in Post Date Women","status":"UNKNOWN","sponsor":"Abdelrahman Ali Fadel Youssef Mohamed","startDate":"2019-03-03","conditions":["Induction of Labor"],"enrollment":100,"completionDate":"2019-07-01"},{"nctId":"NCT02652559","phase":"NA","title":"Initiation of Long-term Non-invasive Ventilation in COPD","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2016-06","conditions":["Chronic Obstructive Pulmonary Disease"],"enrollment":67,"completionDate":"2018-07-25"},{"nctId":"NCT01478022","phase":"PHASE1","title":"To Compare the Pharmacokinetics Profiles of ISO 20, IBU 200 and IBU Plus ISO Combinations 200 + 20","status":"COMPLETED","sponsor":"Parent Project, Italy","startDate":"2011-10","conditions":["Duchenne Muscular Dystrophy (DMD)"],"enrollment":12,"completionDate":"2016-03"},{"nctId":"NCT03523754","phase":"PHASE1,PHASE2","title":"Intravaginal Isosorbide Mononitrate in Addition to Misoprostol Versus Misoprostol Only for Induction of Labor","status":"UNKNOWN","sponsor":"Dina Yahia Mansour","startDate":"2018-01-01","conditions":["Induction of Labor"],"enrollment":50,"completionDate":"2018-11-30"},{"nctId":"NCT03587077","phase":"NA","title":"Pain Relief During IUD Insertion in Women Delivered Only by Elective Cesarean Section","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-09","conditions":["IUD Insertion Complication"],"enrollment":113,"completionDate":"2019-05"},{"nctId":"NCT03557580","phase":"PHASE1","title":"A Bioequivalence Study of Isosorbide-5-Mononitrate Extended-Release Tablets Under Fed Conditions in Healthy Subjects","status":"COMPLETED","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2018-04-17","conditions":["Bioequivalence"],"enrollment":12,"completionDate":"2018-05-18"},{"nctId":"NCT03407521","phase":"PHASE4","title":"Misoprosotol and Isosorbide Mononitrate for Induction of Second Trimester Abortion","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2017-04-12","conditions":["Second Trimester Abortion"],"enrollment":60,"completionDate":"2017-12-15"},{"nctId":"NCT02481323","phase":"PHASE2","title":"Lacunar Intervention Trial 1 (LACI-1)","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2016-03","conditions":["Cerebral Small Vessel Diseases","Cognitive Impairment","Stroke"],"enrollment":57,"completionDate":"2017-11-30"},{"nctId":"NCT03290495","phase":"PHASE4","title":"Ketamine Effect on Isoflurane Anesthesia","status":"COMPLETED","sponsor":"Minia University","startDate":"2017-09-30","conditions":["Post-anesthesia Recovery"],"enrollment":30,"completionDate":"2017-11-25"},{"nctId":"NCT02667535","phase":"PHASE1","title":"PK, PD and Safety Comparative Trial of Isosorbide Mononitrate Gel in Healthy Participants and With Anal Fissure","status":"WITHDRAWN","sponsor":"Biolab Sanus Farmaceutica","startDate":"2017-07","conditions":["Anal Fissure"],"enrollment":0,"completionDate":"2017-11"},{"nctId":"NCT00374621","phase":"NA","title":"Trial of Cervical Ripening and Labor Induction Using Misoprostol With or Without Intravaginal Isosorbide Mononitrate","status":"COMPLETED","sponsor":"Stanford University","startDate":"2006-09","conditions":["Cervical Ripening"],"enrollment":156,"completionDate":"2010-01"},{"nctId":"NCT03072082","phase":"PHASE4","title":"Curative Effect Evaluation of Danlou Tablet on Coronary Artery Disease Not Amenable to Revascularization","status":"UNKNOWN","sponsor":"Jun Li","startDate":"2017-06","conditions":["Coronary Artery Disease(CAD)"],"enrollment":440,"completionDate":"2019-02"},{"nctId":"NCT03072121","phase":"PHASE4","title":"Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization","status":"UNKNOWN","sponsor":"Jun Li","startDate":"2017-06","conditions":["Coronary Artery Disease(CAD)"],"enrollment":440,"completionDate":"2019-02"},{"nctId":"NCT02053493","phase":"PHASE2","title":"Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction","status":"COMPLETED","sponsor":"Adrian Hernandez","startDate":"2014-04","conditions":["Heart Failure"],"enrollment":110,"completionDate":"2015-03"},{"nctId":"NCT02522208","phase":"PHASE1","title":"Pharmacodynamic and Pharmacokinetic Study of BiDil Extended-release Capsules and Commercial BiDil Tablets","status":"COMPLETED","sponsor":"Arbor Pharmaceuticals, Inc.","startDate":"2015-09","conditions":["Heart Failure"],"enrollment":12,"completionDate":"2016-04"},{"nctId":"NCT01961453","phase":"PHASE2","title":"Effect of Isosorbide Mononitrate on Hypertension to Improve Left Ventricular Hypertrophy, Fibrosis and Myocardial Function","status":"WITHDRAWN","sponsor":"Corporal Michael J. Crescenz VA Medical Center","startDate":"2013-08","conditions":["Hypertension"],"enrollment":0,"completionDate":"2016-01"},{"nctId":"NCT00808652","phase":"","title":"Prevalence and Outcome of Brachial Artery Endothelial Function in Morbidly Obese Patients Undergoing Bariatric Surgery","status":"TERMINATED","sponsor":"Sheba Medical Center","startDate":"2009-03","conditions":["Obesity, Morbid","Ischemic Heart Disease"],"enrollment":13,"completionDate":"2014-11"},{"nctId":"NCT02738177","phase":"PHASE2","title":"Misoprostol Versus Effox as Cervical Ripening Agent Prior Surgical Evacuation","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2015-11","conditions":["Cervical Ripening"],"enrollment":90,"completionDate":""},{"nctId":"NCT00000478","phase":"PHASE3","title":"Asymptomatic Cardiac Ischemia Pilot (ACIP) Study","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1990-11","conditions":["Cardiovascular Diseases","Coronary Disease","Heart Diseases","Myocardial Ischemia"],"enrollment":0,"completionDate":"1997-06"},{"nctId":"NCT02718521","phase":"NA","title":"Adequate Hydration Therapy Combined With Intravenous Infusion of Isosorbide Dinitrate Prevention for CIN","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2016-03","conditions":["Cardio-Renal Syndrome"],"enrollment":400,"completionDate":"2017-04"},{"nctId":"NCT02712125","phase":"PHASE2,PHASE3","title":"Nitric Oxide Donors for Treatment of Isolated Oligohydramnios","status":"COMPLETED","sponsor":"Benha University","startDate":"2013-08","conditions":["Isolated (Idiopathic) Oligohydramnios"],"enrollment":100,"completionDate":"2015-08"},{"nctId":"NCT02485340","phase":"NA","title":"The Effect of Sumatriptan and Placebo on Isosorbide-5-mononitrate Induced Headache","status":"COMPLETED","sponsor":"Danish Headache Center","startDate":"2015-04","conditions":["Migraine"],"enrollment":30,"completionDate":"2015-08"},{"nctId":"NCT02368795","phase":"NA","title":"Non-inferiority of Pharmacological Prevention Alone Versus Pancreatic Stents to Prevent Post-ERCP Pancreatitis","status":"UNKNOWN","sponsor":"Tehran University of Medical Sciences","startDate":"2015-02","conditions":["Pancreatitis"],"enrollment":400,"completionDate":""},{"nctId":"NCT01822808","phase":"PHASE3","title":"Bi Treatment With Hydralazine/Nitrates Versus Placebo in Africans Admitted With Acute Heart Failure","status":"UNKNOWN","sponsor":"University of Cape Town","startDate":"2013-01","conditions":["Acute Heart Failure","Left Ventricular Dysfunction"],"enrollment":500,"completionDate":"2016-07"},{"nctId":"NCT01587313","phase":"PHASE1","title":"A Comparison of Various Combinations of BiDil Capsules and BiDil Tablets in Healthy Human Volunteers","status":"COMPLETED","sponsor":"Arbor Pharmaceuticals, Inc.","startDate":"2012-04","conditions":["Healthy"],"enrollment":36,"completionDate":"2012-05"},{"nctId":"NCT00871871","phase":"PHASE1","title":"Multiple Dose Effects of Hydrochlorothiazide and Isosorbide Mononitrate on Glucose Homeostasis (MK-0000-117)(Completed)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-03","conditions":["Hypertension"],"enrollment":64,"completionDate":"2010-03"},{"nctId":"NCT02488642","phase":"PHASE4","title":"Medical Management of Late Intrauterine Death.","status":"COMPLETED","sponsor":"National Institute of Perinatology","startDate":"2008-05","conditions":["Cervical Pregnancy","Maternal Care for Late Fetal Death"],"enrollment":60,"completionDate":"2014-05"},{"nctId":"NCT01387672","phase":"PHASE3","title":"Nitrates and Bone Turnover; Nitrates and Bone Turnover Bisphosphonate Sub-Study","status":"COMPLETED","sponsor":"University of Toronto","startDate":"2011-09","conditions":["Osteoporosis"],"enrollment":265,"completionDate":"2014-12"},{"nctId":"NCT02343393","phase":"PHASE3","title":"Nitrates In Combination With Hydralazine in cardiorEnal Syndrome (NICHE) Study","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2015-01","conditions":["Cardio-Renal Syndrome"],"enrollment":100,"completionDate":"2016-06"},{"nctId":"NCT02258620","phase":"NA","title":"Prevention and Comparison of Different Forms of Administration of Nitrates in the Risk of Radial Spasm During Coronary Angiography.","status":"COMPLETED","sponsor":"Brugmann University Hospital","startDate":"2013-06","conditions":["Coronaropathy"],"enrollment":442,"completionDate":"2014-09"},{"nctId":"NCT00803634","phase":"PHASE3","title":"Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO)","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2008-12","conditions":["Hypertension","Heart Failure"],"enrollment":117,"completionDate":"2012-03"},{"nctId":"NCT01513070","phase":"PHASE4","title":"A Clinical Trials of Quick-Acting Heart Reliever for Moderate Coronary Stenosis","status":"COMPLETED","sponsor":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","startDate":"2012-04","conditions":["Coronary Artery Stenosis","Coronary Heart Disease"],"enrollment":120,"completionDate":"2014-06"},{"nctId":"NCT02152579","phase":"PHASE3","title":"Efficacy and Safety of Monocordil Manufactured by Laboratórios Baldacci","status":"UNKNOWN","sponsor":"Laboratórios Baldacci S.A","startDate":"2014-07","conditions":["Stable Angina"],"enrollment":86,"completionDate":"2014-10"},{"nctId":"NCT02101710","phase":"PHASE1","title":"Pharmacokinetic Properties of Isosorbide-5-mononitrate Under Fasting and Fed Condition in Healthy Male Subjects","status":"COMPLETED","sponsor":"UCB Korea Co., Ltd.","startDate":"2011-06","conditions":["Healthy"],"enrollment":60,"completionDate":"2011-07"},{"nctId":"NCT01631409","phase":"","title":"Estimation of the Long Term Effectiveness of Routine Use of Cardiac Shock Wave Therapy","status":"WITHDRAWN","sponsor":"City Hospital No 40, Saint Petersburg, Russia","startDate":"2013-09","conditions":["Coronary Heart Disease (CHD)"],"enrollment":0,"completionDate":"2021-09"},{"nctId":"NCT01506388","phase":"PHASE3","title":"A Novel Protocol for Labour Induction","status":"COMPLETED","sponsor":"Cairo University","startDate":"2012-02","conditions":["Failed Induction of Labor"],"enrollment":400,"completionDate":"2014-01"},{"nctId":"NCT01676207","phase":"","title":"Prevalence of Extracardiac Coronary Collateral Supply Via the Internal Mammary Arteries","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2012-07","conditions":["Coronary Artery Disease","Collateral Circulation","Ischemia"],"enrollment":120,"completionDate":"2013-12"},{"nctId":"NCT01769079","phase":"PHASE4","title":"Clinical Impact of the Withdrawal of Nitrate in Patients With Stable Angina","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2009-09","conditions":["Stable Angina","Myocardial Ischemia","Quality of Life"],"enrollment":95,"completionDate":"2013-12"},{"nctId":"NCT01430780","phase":"","title":"A Prospective Study to Evaluate the Effect of Chronic Nitrate Therapy on Vasodilation Function in Coronary Heart Disease","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2009-08","conditions":["Coronary Artery Disease"],"enrollment":68,"completionDate":"2013-12"},{"nctId":"NCT00685945","phase":"NA","title":"Renin-Angiotensin Aldosterone System and Fibrinolysis Interaction in Humans-Specific Aim 3","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2007-12","conditions":["Obesity"],"enrollment":24,"completionDate":"2009-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral"},"_patentsChecked":true,"crossReferences":{"NUI":"N0000146900","MMSL":"4933","NDDF":"000687","UNII":"WXR179L51S","VUID":"4018584","CHEBI":"CHEBI:6060","VANDF":"4018584","INN_ID":"6433","RXNORM":"6057","UMLSCUI":"C0022251","chemblId":"CHEMBL1200660","ChEMBL_ID":"CHEMBL1200660","KEGG_DRUG":"D00347","DRUGBANK_ID":"DB09401","PUBCHEM_CID":"5780","SNOMEDCT_US":"108478001","MESH_DESCRIPTOR_UI":"D007547"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1974-","companyName":"Alcon","relationship":"Original Developer"}],"publicationCount":4088,"therapeuticAreas":["Cardiovascular"],"biosimilarFilings":[],"originalDeveloper":"Alcon","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"1974","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1974-01-30T00:00:00.000Z","mah":"ALCON","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1999-09-23T00:00:00.000Z","mah":"ANI PHARMS","brand_name_local":null,"application_number":"ANDA075147"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2011-06-03T00:00:00.000Z","mah":"TORRENT PHARMS","brand_name_local":null,"application_number":"ANDA200270"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-03-12T00:00:00.000Z","mah":"AZURITY","brand_name_local":null,"application_number":"NDA020727"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-04-29T00:00:00.000Z","mah":"SHANDONG","brand_name_local":null,"application_number":"ANDA214115"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-07-14T00:00:00.000Z","mah":"DEXCEL LTD","brand_name_local":null,"application_number":"ANDA210822"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:28:29.482193+00:00","fieldsConflicting":16,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}